Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
PALO ALTO, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK - News) today announced the publication of the positive results from a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with nonsmall cell lung cancer (NSCLC) in a leading peer reviewed publication, the Journal of Thoracic Oncology, October 2009; Vol. 4, No. 10. Data on this study were presented at the 98th annual meeting of the American Association for Cancer Research (AACR) on April 17, 2007.
One hundred twenty-nine patients were treated with TELCYTA in combination with carboplatin and paclitaxel, of whom 100 were continuing to respond at the end of combination therapy and eligible to receive single agent TELCYTA maintenance therapy. Those patients who received the TELCYTA combination therapy followed by TELCYTA maintenance therapy vs. no maintenance therapy had a median progression-free survival (PFS) of 6.8 months vs. 3.9 months, respectively (p< 0.0001). The difference in PFS correlated with a median survival of 16.8 months in the maintenance group vs. 8.8 months for those without maintenance therapy (p<0.0001). TELCYTA in combination with carboplatin and paclitaxel chemotherapy followed by TELCYTA maintenance therapy was well tolerated. TELCYTA may be suited to application as maintenance therapy, an area of current intense interest for the treatment of lung cancer patients. In addition, the regimen appeared active across all types of NSCLC and ongoing investigations are attempting to identify the characteristics of the NSCLC population most likely to benefit from this approach.
--------------------------------------------------
I looked because the stock was up big after hours. I had to do a triple look. Unbelievable what people will fall for these days with a little help from your friendly local manipulator and copywriters from Reuters, etc. 500k shares traded, high of $1.10 closed at $.97.
---------------------------------------------------
Reuters- Telik says early-stage trial data of lung cancer drug positive
Thu Oct 1, 2009 5:13pm EDT
* Drug tested in combination with carboplatin, paclitaxel
* Shares up 33 percent in after-market trade
Oct 1 (Reuters) - Telik Inc (TELK.O) said its drug candidate Telcyta showed positive results in an early-stage trial as a combination therapy for non-small cell lung cancer patients, sending its shares up as much as 33 percent in after-market trade.
Telcyta, in combination with carboplatin and paclitaxel chemotherapy drugs followed by Telcyta maintenance therapy, was well tolerated, the company said in a statement.
Of the 129 patients treated with Telcyta in combination with carboplatin and paclitaxel, 100 continued to respond at the end of the therapy and were eligible to receive single agent Telcyta maintenance therapy, it said.
Shares of the company rose to $1.05 in after market trade. They closed at 79 cents Thursday on Nasdaq. (Reporting by Shailesh Kuber in Bangalore; Editing by Maju Samuel) |
